A response to a previously published article or letter can be submitted to the Online Correspondence section at http://www.anaesthesiacorrespondence.com. A selection of this correspondence is published several times a year in Anaesthesia. All correspondence intended for publication in Anaesthesia should be addressed to Dr David Bogod, Editor-in-Chief, and submitted as an e-mail attachment to firstname.lastname@example.org. For multi-author letters, a covering letter signed by all authors must be submitted either by post, fax (44 (0) 115 962 7670) or by e-mail as a scanned document before correspondence can be published. Alternatively, letters may be submitted typewritten on one side of paper, double spaced with wide margins to Anaesthesia, 1st Floor, Maternity Unit, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. All paper submissions must include a signed covering letter, a disc or CD-ROM with a Word for Windows or .rtf version of the letter and an email address for the corresponding author. Copy should be prepared in the usual style of the Correspondence section. Authors must follow the advice about references and other matters contained in the Author Guidelines at http://www.blackwellpublishing.com/journals/ana/submiss.htm. Correspondence presented in any other style or format will be returned to the author for revision.
Article first published online: 6 JUL 2006
Volume 61, Issue 8, page 819, August 2006
How to Cite
De Vries, F. B. (2006), A reply. Anaesthesia, 61: 819. doi: 10.1111/j.1365-2044.2006.04737_2.x
- Issue published online: 6 JUL 2006
- Article first published online: 6 JUL 2006
Hospira wishes to make the following comment in relation to the letter from Drs Adekanye and Vasoya. Hospira Enterprises BV, the Netherlands, became the marketing authorisation holder in the United Kingdom for noradenaline (Levophed®) as from 01.07.05. The former marketing authorisation holder was Abbott Laboratories Ltd. Hospira, an independent pharmaceutical and medication delivery company, was created in April 2004 from the core global hospital products business of Abbott Laboratories. Since that date Hospira has been separating from Abbott Laboratories in other countries, and in the UK this took place in July 2005. As part of the establishment of the new company, the transfer, of the marketing authorisations needed to take place. During this transfer period and following the actual transfer, a renewal of the licence for norepinephrine (Levophed®) has taken place, and labelling changes were not considered possible during this process. The licence renewal is currently awaiting approval by the MHRA.
Hospira has indicated previously that as soon as it is possible to do so, revisions will be made to the label to address the highlighted concerns. Customers can expect to see the revisions to the product as soon as they can be implemented and a communication will be sent indicating the improvements.